Search Publications

[1] 4th Year Student at CMRU SOLS, Bengaluru. [2] “Hoshinmaru” (Japan v. Russian Federation), Order of 9 July 2007, ITLOS Reports 2005-2007, Application Filed by Japan, p. 7. [3] Law of the Sea Bulletin No. 46, United Nations (2001), pp. 46-47. [4] ”Monte Confurco”, ITLOS Reports 2000, p. 86, at pp. 108-109, para. 74. [5] ITLOS Reports 2000, p. 10, at p. 28, para. 54. [6] ITLOS Reports 2000, p. 86, at p. 109, para. 76. [7] ITLOS Reports 2004, p. 17, at p. 41, para. 85. [8]  “Hoshinmaru” (Japan v. Russian Federation), ITLOS Reports 2005-2007, p. 18 [9] Temple of Preah Vihear, Merits, Judgment, I.C.J. Reports 1962, p. 6, at p. 23. [10] https://leap.unep.org/en/countries/jp/national-case-law/hoshinmaru-case-japan-v-russian-federation

[1] Active and passive euthanasia. (n.d.). [2] Active and passive euthanasia. (n.d.). Retrieved from [3] Batra, H. (n.d.). Euthanasia, Living Will and The Analysis In India. Retrieved from [4] Kothari, A. S. (n.d.). A Comparative Study of Euthanasia in India and Canada: A Critique. [5] Gupta A. (n.d.). Euthanasia — Indian View . [6] QURAN. (n.d.). [7] What Does the Bible Say About Euthanasia? (n.d.). [8] Jainism - Its relevance to psychiatric practice; with special reference to the practice of Sallekhana. (n.d.). [9] Shuriye, A. O. (n.d.). Ethical And Religious Analysis On Euthanasia.

[1] Dr. Rakesh Kumar Singh and Bhanu Pratap, Textbook on Public International Law 251 (LexisNexis, Ghaziabad, 1st edn., 2016, Reprint, 2020) [2] Origin and Development of IHL: History and Philosophy, available at: https://ebooks.inflibnet.ac.in/hrdp08/chapter/origin-and-development-of-ihl-history-and-philosophy/ (Visited on March 28, 2024) [3] History of the ICRC, available at: https://www.icrc.org/en/document/history-icrc (Visited on March 28, 2024) [4] Dr. H.O. Agarwal, Human Rights 233 (Central Law Publications, Allahabad, 14th edn., 2013) [5] V K Ahuja, Public International Law 264 (Lexis Nexis, Noida, 1st edn., 2016) [6] Charter of the International Military Tribunal, 1945, Art. 6 [7] Dr. S.K. Kapoor, International Law and Human Rights 777 (Central Law Agency, Prayagraj, 22nd edn., 2021) [8] Ibid., 778 [9] Supra note 7 [10] Supra note 1, p. 245 [11] What is IHL?, available at: https://www.icrc.org (Visited on March 31, 2024) [12] Supra note 1, p. 248 [13] Supra note 1, p. 249 [14] Supra note 4, p. 236 [15] First Geneva Convention, Art. 3(1) [16] Ibid., Art. 3(1) [17] Ibid., Art. 12 [18] Ibid., Art. 15(3) [19] Ibid., Art. 19(1) [20] Ibid., Art. 33 [21] Ibid., Art. 35 [22] Ibid., Art. 38-44 [23] Second Geneva Convention, Art. 3(1) [24] Ibid., Art. 1 [25] Ibid., Art. 18 [26] Ibid., Art. 51 [27] Prisoners of War, available at: http://casebook.icrc.org (Visited on March 31, 2024) [28] Third Geneva Convention, Art. 23 [29] Ibid., Art. 22 [30] Ibid., Art. 97 [31] Ibid., Art. 26 [32] Ibid., Art. 13-14 [33] Ibid., Art. 17 [34] Ibid., Art. 88 [35] Fourth Geneva Convention, Art. 14 [36] Ibid., Art. 27 [37] Ibid., Art. 31 [38] Ibid., Art. 33,34 [39] Ibid., Art. 136-141 [40] Ibid., Art. 140 [41] Ibid., Art. 25 [42] Ibid., Art. 27 [43] Ibid., Art. 50 [44] Additional Protocol I, 1977, Art. 35(3), 55(1) [45] Ibid., Art. 52(1) [46] Ibid., Art. 54(1) [47] Ibid., Art. 54(4) [48] Ibid., Art. 70 (2) [49] Ibid., Art. 51(2) [50] Ibid., Art. 51(7) [51] Additional Protocol II, 1997, Art. 4(1) [52] Ibid., Art. 18(1) [53] Ibid., Art. 4(2) [54] Ibid., Art. 13 [55] Ibid., Art. 14 [56] Ibid., Art. 15 [57] Ibid., Art. 17

[1] Student at Alliance University, Bangalore [2] 4 SCC 158 [3] (2010) 6 SCC 1; (2010) 2 SCC (cri) 1385 [4] https://presscouncil.nic.in/Pdf/Press%20council%20act.pdf

[1] U.S. Food and Drug Administration, What are Generic Drugs? [2] Ibid. [3] Das M, Choudhury S, Maity S, Hazra A, Pradhan T, Pal A, Roy RK. Generic versus Branded Medicines: An Observational Study Among Patients with Chronic Diseases Attending a Public Hospital Outpatient Department. J Nat Sci Biol Med. 2017 Jan-Jun;8(1):26-31. doi: 10.4103/0976-9668.198351. PMID: 28250671; PMCID: PMC5320819. [4] Aswini Priya, "The Role of Generic Medicines in Bridging Healthcare Gaps on a Global Scale," Invimeds (Mar. 01, 2024), https://invimeds.com/updates/the-role-of-generic-medicines-in-bridging-healthcare-gaps-on-a-global-scale/. (last visited Mar. 15, 2024) [5] Ibid [6] George, Thomas & Baliga, Shrinath. (2021). Generic Anticancer Drugs of the Jan Aushadhi Scheme in India and Their Branded Counterparts: The First Cost Comparison Study. Cureus. 13. e19231. 10.7759/cureus.19231. [7] Yuxi Tian, Berthold Reichardt, Daniela Dunkler, Milan Hronsky, Wolfgang C. Winkelmayer, Anna Bucsics, Susanne Strohmaier & Georg Heinze, Comparative effectiveness of branded vs. generic versions of antihypertensive, lipid-lowering and hypoglycemic substances: a population-wide cohort study, Sci Rep 10, 5964 (2020). [8] Ibid. [9] Government of India, Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals, 'Jan Aushadhi Scheme: Making Medicines Affordable for All,' Indian Journal of Pharmaceutical Sciences (2021), https://janaushadhi.gov.in/article.php?id=1234 [10] Parliamentary Standing Committee on Health and Family Welfare, Forty-Fifth Report on Issues Relating to Availability of Generic, Generic-Branded and Branded Medicines, their Formulation and Therapeutic Efficacy and Effectiveness, Aug. 4, 2010. [11] U.S. Food and Drug Administration, Understanding Generic Drugs, https://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs/ (last visited Jan. 15, 2024). [12] Puskar, Generic Drugs – Why is it Important?, (Oct. 23, 2011) http://greencleanguide.com/generic-drugs/ [13] Viral Shah, Evolution of Pharmaceutical Industry: An Indian Perspective 2 JPSBR: Issue 5, 219, 229 (2012). [14] Pradeep Agarwal and P. Saibaba, TRIPS and India’s Pharmaceutical Industry, Economic and Political Weekly, Vol.36, No.39 (Sep. 29- Oct. 5, 2001), 3787 [15] Richard A. Spinello, Ethics, Pricing and the Pharmaceutical Industry, The Journal of Law & Economics, Vol.43, No.2 (October 2000), 311. [16] Ibid. [17] Ibid. [18] Sanjaya Lall, Multinational Companies and Concentration: The Case of the Pharmaceutical Industry, Social Scientist, Vol.7, No.8/9, (Mar. – Apr, 1979), pp.3-29. [19] Ibid. [20] Viral Shah, Evolution of Pharmaceutical Industry: An Indian Perspective 2 JPSBR: Issue 5, 219, 229 (2012). [21] Ibid. [22] National pharmaceutical pricing authority. https://pharmaceuticals.gov.in/national-pharmaceutical-pricing-authority 2013;13 [Google Scholar] [23] Bhaskarabhatla A, Chatterjee C, Anurag P, Pennings E, Mitigating regulatory impact: the case of partial price controls on metformin in India. Health Policy Plan. 2017;32:194–204 [24] Ahmad A, Khan MU, Patel I., Drug pricing policies in one of the largest drug manufacturing nations in the world: are affordability and access a cause for concern? J Res Pharm Pract. 2015;4:1–3. [25] Bharuga M., An overview on the National Pharmaceutical Pricing Policy. http://www.iclr.in/assets/pdf/AN%20OVERVIEW%20ON%20THE%20NATIONAL%20PHARMACEUTICAL%20PRICING%20POLICY,%202012.pdf 2012, (last visited 01 Mar, 2024) [26] Ibid [27] Ibid [28] National list of essential medicines of India. https://pharmaceuticals.gov.in/sites/default/files/NLEM.pdf 2011 [29] An overview on the National Pharmaceutical Pricing Policy. Bharuga M. http://www.iclr.in/assets/pdf/AN%20OVERVIEW%20ON%20THE%20NATIONAL%20PHARMACEUTICAL%20PRICING%20POLICY,%202012.pdf, (last visited 01 Mar, 2024) [30] Guan X, Wushouer H, Yang M, Han S, Shi L, Ross-Degnan D, Wagner AK. Influence of government price regulation and deregulation on the price of antineoplastic medications in China: a controlled interrupted time series study. BMJ Open. 2019;9:0. [31] Hsu JC, Wei CF, Yang SC, Effects of removing reimbursement restrictions on targeted therapy accessibility for non-small cell lung cancer treatment in Taiwan: an interrupted time series study. BMJ Open. 2019;9:0. [32] Bhaskarabhatla A, Chatterjee C, Anurag P, Pennings E. Mitigating regulatory impact: the case of partial price controls on metformin in India. Health Policy Plan. 2017;32:194–204. [33] Selvaraj S, Farooqui HH, Mehta A. Does price regulation affect atorvastatin sales in India? An impact assessment through interrupted time series analysis. BMJ Open. 2019;9:0. [34] https://janaushadhi.gov.in/pmjy.aspx (last visited Mar. 11, 2024). [35] Ibid. [36] Government of India, Ministry of Chemicals and Fertilizers, Department of Pharmaceuticals, Annual Report 2021-22 available at https://janaushadhi.gov.in/annual_report.aspx  (last visited Mar. 11, 2024) [37] Ibid. [38] Sajitha Venkatesan, Most recent cancer drugs offer few benefits, India’s top cancer hospital says, BMJ 2017;357:j2129 [39] https://www.business-standard.com/content/b2b-pharma/govt-plans-to-open-300-amrit-pharmacies-to-dispense-low-cost-drugs-116081600610_1.html (last visited, 15. Mar. 2024) [40] Parmar A, Pal A, Sharma P. National List of Essential Medicines 2022 of India: Perspectives from Psychiatrists. Indian J Psychol Med. 2023 Jul;45(4):411-414. doi: 10.1177/02537176231155328. Epub 2023 Feb 16. PMID: 37483582; PMCID: PMC10357919. [41] Marcolino MS, Oliveira JAQ, D'Agostino M, Ribeiro AL, Alkmim MBM, Novillo-Ortiz D. The Impact of mHealth Interventions: Systematic Review of Systematic Reviews. JMIR Mhealth Uhealth. 2018 Jan 17;6(1):e23. doi: 10.2196/mhealth.8873. PMID: 29343463; PMCID: PMC5792697.